Kewei Liu
Qingdao, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma.
Journal: The oncologist
Published: February 02, 2022
Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 30, 2021
Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 1 Diabetes Mellitus.
Journal: Clinical drug investigation
Published: July 30, 2020
Apatinib in Combination with S-1 as First-Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single-Arm, Phase II Trial.
Journal: The oncologist
Published: July 21, 2020
Loss of ARID1A expression promotes lung adenocarcinoma metastasis and predicts a poor prognosis.
Journal: Cellular oncology (Dordrecht, Netherlands)
Published: May 27, 2020
Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC.
Journal: Cancer management and research
Published: January 14, 2019
The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis.
Journal: Cancer management and research
Published: October 08, 2018
Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma.
Journal: Oncotarget
Published: July 04, 2016
Prognostic significance of the co-expression of nucleophosmin and trefoil factor 3 in postoperative gastric cancer patients.
Journal: Molecular and clinical oncology
Published: May 22, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026